Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C26H31N3O5
CAS Number:
Molecular Weight:
465.54
UNSPSC Code:
12352200
MDL number:
NACRES:
NA.21
InChI
1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)
InChI key
NDAZATDQFDPQBD-UHFFFAOYSA-N
SMILES string
O=C(C1=NOC(C2=C(O)C=C(O)C(C(C)C)=C2)=C1C3=CC=C(CN4CCOCC4)C=C3)NCC
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
High-affinity, potent and selective heat shock protein 90 (HSP90α/β) inhibitor with anti-cancer efficacy in cultures and in vivo.
NVP-AUY922 (Luminespib; VER-52296) is a high-affinity (HSP90β Kd = 1.7 nM), potent and selective heat shock protein 90 inhibitor (HSP90α/β Ki = 9.0/8.2 nM, HSP90α/β IC50 = 7.8/21 nM) that exhibits anti-proliferation potency in cancer cultures (GI50 from 2 to 40 nM among 29 cancer lines) and anti-tumor efficacy in vivo (50-75 mg/kg/day i.p.) by inducing cancer cells G1-G2 arrest and apoptosis.
NVP-AUY922 (Luminespib; VER-52296) is a high-affinity (HSP90β Kd = 1.7 nM), potent and selective heat shock protein 90 inhibitor (HSP90α/β Ki = 9.0/8.2 nM, HSP90α/β IC50 = 7.8/21 nM) that exhibits anti-proliferation potency in cancer cultures (GI50 from 2 to 40 nM among 29 cancer lines) and anti-tumor efficacy in vivo (50-75 mg/kg/day i.p.) by inducing cancer cells G1-G2 arrest and apoptosis.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Brittany Epp-Ducharme et al.
Scientific reports, 11(1), 11103-11103 (2021-05-29)
The heat shock protein 90 inhibitor, luminespib, has demonstrated potent preclinical activity against numerous cancers. However, clinical translation has been impeded by dose-limiting toxicities that have necessitated dosing schedules which have reduced therapeutic efficacy. As such, luminespib is a prime
Suzanne A Eccles et al.
Cancer research, 68(8), 2850-2860 (2008-04-17)
We describe the biological properties of NVP-AUY922, a novel resorcinylic isoxazole amide heat shock protein 90 (HSP90) inhibitor. NVP-AUY922 potently inhibits HSP90 (K(d) = 1.7 nmol/L) and proliferation of human tumor cells with GI(50) values of approximately 2 to 40
Michael Rugaard Jensen et al.
Breast cancer research : BCR, 10(2), R33-R33 (2008-04-24)
Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis. HSP90 has emerged in recent years as
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service